IDEAYA Biosciences, Inc.
NASDAQ:IDYA · NASDAQ Global Select
-$0.45 today
Vol 1.48M · Avg 1.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.1%
avg -0.2%
ROIC
-15.2%
avg -32.2%
ROA
-10.2%
avg -25.8%
Analysis
ROA is currently the strongest return metric at -10.2% versus its period average of -25.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Yujiro S. Hata | Founder, President, Chief Executive Officer & Director | $1.09M | — | 52 | $600,000.00 | 0.63% |
Darrin Beaupre | Chief Medical Officer | $738,300.00 | — | 59 | $175,000.00 | 0.18% |
Michael A. White | Chief Scientific Officer | $728,300.00 | — | 61 | $190,000.00 | 0.20% |
Joshua Bleharski | Chief Financial Officer | $683,347.00 | — | 51 | $170,000.00 | 0.18% |
Douglas Snyder | Chief Legal Officer | $668,523.00 | — | 62 | $130,000.00 | 0.14% |
Andres Ruiz Briseno | Chief Accounting Officer | $600,800.00 | — | 40 | $80,000.00 | 0.08% |
Stuart Dorman | Chief Commercial Officer | $161,817.00 | — | 48 | $155,000.00 | 0.16% |
Jasgit Sachdev | Senior Vice President of Late Phase Clinical Development & Strategy | — | — | — | — | — |
Paul A. Barsanti | Chief Technology Officer | — | — | — | $9,303.00 | <0.01% |
Theodora Ross | Chief Development Officer | — | — | — | $0.00 | <0.01% |
Daniel A. Simon | Chief Business Officer | — | — | — | $9,303.00 | <0.01% |
Mick O'Quigley | Senior Vice President of Medical Writing & Project Management | — | — | — | — | — |
Claire L. Neilan DABT | Senior Vice President of Preclinical Sciences | — | — | — | $16,200.00 | 0.02% |
Francine Zelaya | Senior VP & Head of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.65M
Sells
0
$0.00
Net Sentiment
+$1.65M
Net buying
Most Active
Stein Jeffrey
1 transactions
Analysis
Insiders reported 1 buys worth $1.65M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.65M. Stein Jeffrey was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +49.2% (9yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +49.2% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.88B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.63B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Legend Biotech Corporation
NASDAQ:LEGN
$5.30B
Amicus Therapeutics, Inc.
FOLD
$4.55B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$4.13B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.40B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.79B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.69B
Who manages IDYA?
IDEAYA Biosciences, Inc. (IDYA) lists 14 active executives. The top listed executive is Douglas Snyder, Chief Legal Officer.
Are IDYA insiders buying or selling?
Recent insider activity shows net buying of $127.13M.
Explore More
Continue the stock analysis
Jump to another research area for this company.